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Objective. To assess the growth and control of adrenal androgen secretion in children with virilizing congenital adrenal hyperplasia
(CAH) treated with dexamethasone. Method. We examined doses used, control of adrenal androgen secretion, and growth and
skeletal maturation of 8 children with CAH treated with dexamethasone beginning in infancy. Results. 3 boys and 5 girls with
classical CAH (17-hydroxyprogesterone at diagnosis >20,000 ng/dL) were treated with dexamethasone beginning at diagnosis (<10
days of age). Patients were also treated with fludrocortisone and sodium chloride. The average initial medication dose was 0.1 mg
(0.28±0.015 mg/m2); all doses were given in the morning using a dosing syringe to administer a 0.1 mg/mL elixir. The children were
treated for 6.5±2.0 years over which time the change in bone age to chronological age ratio (ΔBA/ΔCA) was 0.9±0.06. Most recent
height Z’ scores were +0.5±0.2, and body mass index (BMI) scores were 18±0.2. Late afternoon levels of 17-hydroxyprogesterone,
androstenedione, and testosterone were 780± 238 ng/dL (23.4± 7 nmol/L), 42± 10 ng/dL (1.4± 0.3 nmol/L), and 11.5± 3 ng/dL;
(0.4± 0.1 nmol/L), respectively. Conclusions. These observations show that low doses of dexamethasone can be used to eﬀectively
treat CAH beginning in infancy.
Copyright © 2009 S. A. Rivkees and K. Stephenson. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. Introduction
Congenital adrenal hyperplasia (CAH) is characterized by
the inability to produce adequate amounts of glucocorticoids
and mineralocorticoids, and reciprocal excessive production
of androgens [1–3]. Untreated, CAH can result in adrenal
crisis attended by circulatory collapse and hypoglycemia [1–
3]. Excessive androgen production can result in a prenatal
and postnatal virilization [1–3]. As result, treatment of CAH
is essential for the well being of the child.
Mainstays of CAH therapy include treatment with glu-
cocorticoids and mineralocorticoids. To date, the majority of
patients with CAH have been treated with hydrocortisone,
which is a compound with a short circulating half-life
[4, 5]. The use of longer acting glucocorticoids including
prednisone and dexamethasone has also been reported
[6–8]. Caution, though, has been recommended in using
prednisone and dexamethasone due to the high potency of
these compounds [4, 5].
When applied in the treatment of CAH, the relative
potency of prednisone to hydrocortisone of 4 to 5 to
1 has been used by some groups [6]. The potency of
dexamethasone relative to hydrocortisone has been regarded
to be approximately 30 to 1 [9]. However, these are
anti-inflammatory, not anti-adrenal potencies [10]. Rather,
prednisone is approximately 15 times more potent than
hydrocortisone [8] and dexamethasone is 80 to 100 fold
more potent [7] than hydrocortisone in suppressing adrenal
androgen production.
The use of dexamethasone in the treatment of CAH was
introduced in 1971 [11]. Subsequent studies have shown
that dexamethasone can control excessive adrenal androgen
production used once a day, making this form of treatment
convenient for families [7].
In 2000 we reported our experience using dexametha-
sone for the treatment of 26 boys and girls with CAH [7]. The
average dose used to treat these patients was 0.27 mg/m2/day,
with doses given in the morning [7]. On this regimen, there
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Table 1: Circulating adrenal hormone levels for infants treated with dexamethasone for CAH.
Hormone Normal prepubertal levels∗ Infants with CAH Fold increase
17-OHP
(ng/dL) 40 (3–100) 780 ± 238
20-fold
(nmol/L) 1.4 (0.09–3) 23.4 ± 7
Androstenedione
(ng/dL) 25 (8–50) 42 ± 10
1.7-fold
(nmol/L) 1 (0.32–2) 1.4 ± 0.3
Testosterone
(ng/dL) 5 (3–10) 11.5 ± 3
2.2-fold
(nmol/L) 0.17 (0.1–0.3) 0.4 ± 0.1
∗From Esoterix Laboratory Services, Inc.
was comparable maturation of linear and skeletal growth [7].
That population of children included individuals who had
treatment onset at 2.8 years of age [7]. Those studies did
not report our experience of dexamethasone used in infants
treated from infancy onward. We now report the outcome of
children with CAH treated with dexamethasone beginning at
birth.
2. Methods
This analysis was approved by the Yale Human Investigation
Committee. The medical records of all patients with a
diagnosis of CAH were evaluated. Patients were included for
analysis if they were treated continuously with dexametha-
sone from infancy onward.
Dexamethasone was administered at initial dose of
0.1 mg each morning. A 0.1 mg/mL elixir of generic dexam-
ethasone was used. Doses were administered between 7:00
and 9:00 a.m. using a dosing syringe. When the patients
were ill, parents were instructed to give a double dose in the
morning, and the same double dose in the evening for the
duration of illness plus one day.
Patients were evaluated clinically every three to four
months at which time height, weight, and blood pressure
were assessed. Laboratory tests were obtained between 3:00
and 5:00 p.m. for determination of circulating concentra-
tions of 17-hydroxyprogesterone, androstenedione, testos-
terone, renin, and electrolytes. All hormonal determinations
were performed at commercial diagnostic laboratories (Eso-
terix Life Sciences or Quest Laboratories). Every six months,
after the age of one year, radiographs of the left hand and
wrist were obtained for bone age determination using the
Greulich and Pyle atlas [12]. Radiographs were interpreted
by pediatric radiologists who were unaware of the clinical
condition of the children.
Doses were increased when the 17-hydroxyprogesterone
levels were above 1,000 ng/dL and the androstenedione and
testosterone levels were more than 2-fold above normal.
Doses were decreased when the 17-hydroxyprogesterone
levels were less than 250 ng/dL and the androstenedione
and testosterone levels were normal or below normal, or
there was excessive weight gain assessed at home (>0.5 kg
in 2 weeks). When dose adjustments were made, doses were
generally changed by 10%. Laboratory testing was repeated 2
months after dose changes.
All data pertaining to height, weight, drug doses, and
laboratory test results were extracted from medical records
and were recorded in an Excel data spread sheet. Height
and body mass index (BMI) Z scores were determined using
United States National Center for Health Statistics (NCHS)
reference charts. Data are presented as mean ± SEM.
3. Results
Three boys and five girls were identified as having CAH
by newborn screening and treated with dexamethasone
from birth. The average 17-hydroxyprogesterone levels were
58,400 ± 12,000 ng/dL at 48 hours of age. In all patients, the
diagnosis of congenital adrenal hyperplasia was confirmed
by repeat measurement of 17-hydroxyprogesterone levels
and/or ACTH stimulation testing using standard criteria
[13]. The average age at diagnosis and treatment onset was
8 ± 2 days.
Seven infants were diagnosed with 21-hydroxylase defi-
ciency; one infant had 11-hydrolase deficiency. The average
Prader score of girls was 3.2 ± 0.3. The individual with 11-
hydroxylase deficiency was Prader stage 4 at diagnosis. All
patients were also treated with 0.1 mg of fludrocortisone once
daily, plus 1.5 mL, three or four times a day, of 23% sodium
chloride solution orally.
For the patients with 21-hydroxylase deficiency, average
late-afternoon 17-hydroxyprogesterone levels were 780 ±
238 ng/dL (23.4 ± 7 nmol/L) (Table 1). Androstenedione
levels were 42 ± 10 ng/dL (1.4 ± 0.3 nmol/L). Testosterone
levels were 11.5 ± 3 ng/dL (0.4 ± 0.1 nmol/L). [Normal
levels for prepubertal individuals: 17-hydroxyprogesterone
40 ng/dL, range 3 to 100; (1.4 nmol/L, range 0.09 to 3);
androstenedione, 25 ng/dL, range of 8 to 50 (1 nmol/L,
range 0.32 to 2); testosterone, 5 ng/dL, range of 3 to 10
(0.17 nmol/L; range 0.1 to 0.3)].
When the linear growth was evaluated, growth rate Z
scores were 1.1 ± 0.1 (Table 2). At an average of 6.5 years
of age, height Z scores were 0.5 ± 0.2 and the average body
mass index (BMI) was 18.2 ± 1.5. The mean bone age was
5.1 ± 1.5 years, with a bone age to chronologic age ratio of
0.9 ± 0.6 years (Figure 1).
When begun on a dose of 0.1 mg of dexamethasone each
morning, seven patients did not require a change in the
dexamethasone dose until 1.5 years of age. In one child,
the dexamethasone dose was reduced at six months of age,
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Table 2: Clinical Characteristics of patients at end of observation
period.
Age (yrs) 6.5 ± 2
Height Z score 0.5 ± 0.2
Growth velocity Z score 1.1 ± 0.1
BMI 18.2 ± 1.5
Bone age (yrs) 5.1 ± 1.5
BA/CA 0.9 ± 0.6











Figure 1: Bone age (BA) versus chronological age (CA) in
individual children treated with dexamethasone for CAH. Dashed
line is the line of unity.
as the child developed excessive weight gain. In one patient,
only one dose change was made in the 5-year follow-up
period; in three patients, two dose changes were made in six
years; in three patients, three dose changes were made in six
years; in one patient seven dose changes were made in eight
years. At an average of 6.5 years of age, the average daily dose
of dexamethasone was 0.18 ± 0.5 mg/m2/d.
No patients required hospitalization for treatment of
adrenal insuﬃciency. One child was hospitalized for treat-
ment of gastroenteritis at 3 years of age for 24 hours. When
restorative surgery was performed, patients were placed on
stress dosing for 48 hours post operatively.
4. Discussion
Our results show that infants with CAH can be managed
with once a day, low-doses of dexamethasone. We show that
infants treated with low doses of dexamethasone for CAH
have normal linear growth, skeletal maturation, and weight
gain.
The use of long-acting glucocorticoids in the treatment
of individuals with CAH has been greeted with controversy
[4, 5]. A large part of this controversy rests on the mistaken
assumption that prednisone is 5 times more potent than
hydrocortisone, and that dexamethasone is 30 times more
potent than hydrocortisone in suppressing adrenal androgen
production. These literature entrenched equivalencies are
based on anti-inflammatory properties [9]. However, as
observed more than 40 years ago by Wilkins and coworkers
[10], prednisone and dexamethasone are 10- and 80-fold
more potent than hydrocortisone, in suppressing adrenal
androgen production, respectively. When prednisone and
hydrocortisone are used at 5- and 30-fold potencies relative
to hydrocortisone, children will be over treated, as reflected
in a recent report detailing the use of prednisone during
adolescence [9].
The average dose initially used for treating the infants
with dexamethasone was 0.25 mg/m2/day. (In comparison,
most infants treated with hydrocortisone during infancy are
treated with 20 mg/m2/day [14–16].) As the infants became
older, most remained on a dexamethasone dose within 30%
of the dose started in infancy. Thus, at the end of the follow-
up period, the average daily dose of dexamethasone was
0.18 mg/m2/day. For children treated with hydrocortisone for
CAH, typical doses are 15–20 mg/m2/day [5]. Thus, com-
pared with standard hydrocortisone doses, dexamethasone is
80–100 fold more potent than hydrocortisone.
On low doses of dexamethasone, linear growth was
normal in all children. Body mass index scores were normal
in all children, indicating that the children gained weight
normally.
When circulatory androgen levels were assessed, they
were measured at the end of the day. Testing was performed
at this time, as over the years we assessed circulating
hormone levels at diﬀerent times of the day, and we
found that late afternoon levels correlated best with dose
adjustments that allowed us to optimize growth and normal
weight gain. At late afternoon, circulating testosterone and
androstenedione levels were close to, or 2-fold above the
normal range. The 17-hydroxyprogesterone levels were 10-
to 20-fold above normal.
Previous studies have evaluated long-term linear growth
in individuals treated with the short-acting glucocorticoid
hydrocortisone [16]. In general, these studies reveal final
adult heights are 1 to 2 standard deviations below that
expected [16]. In our previous studies of older children
treated with dexamethasone for CAH, we observed final
or projected final height standard deviations scores of 0.2
[7]. In the current study, the bone ages were slightly
less than the chronological ages. Thus, based on growth
and skeletal maturation parameters, the linear growth in
dexamethasone-treated children appears normal. Long-term
follow-up of these children will be needed to ascertain long-
term outcomes more than one decade from now.
Although we show that dexamethasone can be used
to eﬀectively treat CAH, it is important to emphasis that
dexamethasone is a very potent glucocorticoid and overtreat-
ment can occur. To avoid overtreatment, it is imperative that
the dilute elixir (0.1 mg/mL) be used, and the dose should
be administered with a syringe. Although it is tempting to
give the dose at night to suppress morning adrenal androgen
production, nighttime dosing of dexamethasone is associated
with overtreatment [17]. Thus, the morning is the favored
time for administration. When dose changes are made,
changes are by 10% to 20%, and we instruct families to
monitor the child’s weight with a scale at home. If the weight
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increases by 0.5 kg over two weeks, the dose is empirically
reduced.
In summary, we show that treatment of virilizing CAH
from infancy onward with low-dose dexamethasone is
eﬀective. Children treated with low doses of dexamethasone
for CAH have normal linear growth, weight gain, and
appropriate skeletal maturation. The convenience of once
a day dosing, and the relatively few dose changes that are
needed over the first several years of life contribute to
a favorable regimen for the treatment of infants. Further
studies involving larger numbers of children are indicated
to assess the utility for this approach before it is broadly
applied.
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